What are the adverse reactions of durvalumab/Infinifer?

Durvalumab/Infinifer (Durvalumab) is an immune checkpoint inhibitor, and its adverse reactions are mainly related to immune system activation. Unlike traditional chemotherapy, durvalumab works by removing the inhibition of T cells by tumors, so its side effects are often reflected in immune-related reactions, including the skin, endocrine system, lungs and digestive system.

Common adverse reactions include mild to moderate rash, pruritus, and fatigue. Most of these reactions are controllable and reversible and are usually relieved by topical care or symptomatic treatment. In addition, some patients may develop immune-related endocrine abnormalities, such as thyroid function changes or adrenal gland dysfunction, which requires regular monitoring of blood indicators and hormone replacement or supportive treatment if necessary. Regarding the respiratory system, durvalumab may cause immune-related pneumonitis, manifested by cough, shortness of breath, or dyspnea, requiring imaging and early intervention. Abnormal liver function and digestive system discomfort are also potential risks and need to be detected promptly through laboratory testing.

It is worth noting that most adverse reactions can be effectively managed during treatment, and doctors will decide whether to continue, adjust the dose, or temporarily discontinue the drug based on the severity of symptoms. Patients should maintain regular follow-up while taking durvalumab, including hematology tests, imaging reviews, and symptom records, in order to detect abnormal reactions early. Timely communication and standardized management are the keys to ensuring the safety of immunotherapy.

In general, although the adverse reactions of durvalumab involve multiple systems, through scientific monitoring and early intervention, most patients can safely and continuously benefit from treatment. Understanding the types and management methods of side effects can help patients prepare mentally and physically during treatment, improve compliance, and ensure the efficacy and safety of immunotherapy.

Reference materials:https://www.imfinzi.com/